How It Works Insulin Potentiation Therapy +Targeted Low Dose Therapy IPTLD or IPT, is a true Stage IV alternative cancer treatment. It uses a combination of two orthodox drugs - insulin (actually insulin is also found in nature) and a chemotherapy drug. Cancer cells have highly active insulin receptors.
With IPTLD the insulin works on the cell membranes and allows chemotherapy to target cancer cells. Thus, it is the chemotherapy that kills the cancer cells, however, because of the insulin, the amount of chemotherapy needed is greatly reduced, meaning the side-effects of the chemotherapy are greatly reduced. Thus, the chemotherapy is much more potent (thus the word: potentiation), much less chemotherapy is needed, and far less side-effects are experienced.
Insulin is truly a "magic bullet" cancer treatment, meaning it allows chemotherapy to target cancer cells and results in far less side-effects.
The word "potentiate" means that one substance (insulin) enhances the effectiveness of another agent (chemotherapy) and thus far less of the second agent (chemotherapy) is needed. This means far less side-effects, as well as a more effective treatment, is the result of a potentiating substance.
"Because of this favorable side effect profile, cycles of low-dose chemotherapy with IPTLD may be done more frequently."
Not only is IPTLD more effective than normal chemotherapy, it can be administered more frequenly, but with less side-effects.
Consider the following doses of chemotherapy required by orthodox medicine versus IPTLD therapists (i.e. orthodox dose to IPTLD dose):
1) Doxorubicin (100 mg to 10 mg)
2) 5-Fluorouracil (1,500 mg to 200 mg)
3) Cyclophosphamide (1,500 mg to 200 mg)
4) Methotrexate (60 mg to 10 mg)
5) Cisplatin (150 mg to 15 mg)
"In those undergoing treatment with IPT, an overall gentler experience promotes their concurrent use of other important elements in a program of comprehensive cancer care, which includes nutrition for immune system support and mind-body medicine to encourage a healing consciousness.
- S. Ayre, M.D., quoted in Treating Cancer with Insulin Potentiation Therapy page 17
- "There are numerous conditions that affect the central nervous system, including strokes (also called cerebrovascular accidents), transient ischemic attacks, multiple sclerosis, Alzheimer's disease, dementia, amyotrophic lateral sclerosis (Lou Gehrig disease), and transverse myelitis, as well as infections from Borrelia (Lyme disease), syphilis, herpes, HIV (human immunodeficiency virus), and many other organisms. As seen from this list, the treatment options for these diseases are very scarce. The primary reason that treatments for these disorders are almost nonexistent is that most medications do not adequately pass the blood-brain barrier. The blood-brain barrier retards the entry of many compounds into the brain, including chemotherapeutic agents. Theoretically, if there was a way to increase the transport of substances into the central nervous system and through the barrier, the efficacy of treatment would be greatly enhanced."
Treating Cancer With Insulin Potentiation Therapy, Page 84
In the "old days" IPTLD therapy required the patient to be put into an "insulin coma." During those days orthodox medicine was somewhat (but not very much) justified in avoiding IPTLD. But today, if you find an IPTLD doctor who requires you to be put into an insulin coma, find another doctor. It is no longer necessary to be put into an insulin coma.
With their justification of an "insulin coma" now gone, orthodox medicine has no excuse for not supporting IPTLD. It is faster working, far more effective and has virtually zero side-effects. It's "true cure rate" is much, much higher than the "true cure rate" of orthodox medicine of 3%.
It is strongly recommended to anyone considering IPTLD to buy and study the SUPERB book:
Treating Cancer With Insulin Potentiation Therapy by Ross A. Hauser, M.D. and Marion A. Houser, M.S., R.D.